deltatrials
Completed PHASE3 Interventional 1-arm NCT03392142

Tabelecleucel for Allogeneic Hematopoietic Cell Transplant Subjects With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease (EBV+ PTLD) After Failure of Rituximab (MATCH)

Multicenter, Open-Label, Phase 3 Study of Tabelecleucel for Allogeneic Hematopoietic Cell Transplant Subjects With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure of Rituximab

Sponsor: Atara Biotherapeutics

Conditions Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease (EBV+ PTLD) Lymphoproliferative Disorders Stem Cell Transplant Complications
Interventions tabelecleucel
Updated 21 times since 2018 Last updated: Mar 24, 2021 Started: Dec 29, 2017 Primary completion: Feb 16, 2021 Completion: Feb 16, 2021
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease (EBV+ PTLD) and Lymphoproliferative Disorders and is currently completed. Atara Biotherapeutics leads this study, which shows 21 recorded versions since 2017 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

~Jan 2018 – ~Mar 2018 · 59 days · monthly snapshot~Mar 2018 – ~May 2018 · 2 months · monthly snapshot~May 2018 – ~Jun 2018 · 31 days · monthly snapshot~Jun 2018 – ~Jul 2018 · 30 days · monthly snapshot~Jul 2018 – ~Sep 2018 · 2 months · monthly snapshot~Sep 2018 – ~Oct 2018 · 30 days · monthly snapshot~Oct 2018 – ~Nov 2018 · 31 days · monthly snapshot~Nov 2018 – ~May 2019 · 6 months · monthly snapshot~May 2019 – ~Jun 2019 · 31 days · monthly snapshot~Jun 2019 – ~Aug 2019 · 2 months · monthly snapshot~Aug 2019 – ~Dec 2019 · 4 months · monthly snapshot~Dec 2019 – ~Jan 2020 · 31 days · monthly snapshot~Jan 2020 – ~Jun 2020 · 5 months · monthly snapshot~Jun 2020 – ~Jul 2020 · 30 days · monthly snapshot~Jul 2020 – ~Aug 2020 · 31 days · monthly snapshot~Aug 2020 – ~Sep 2020 · 31 days · monthly snapshot~Sep 2020 – ~Oct 2020 · 30 days · monthly snapshot~Oct 2020 – ~Dec 2020 · 2 months · monthly snapshot~Dec 2020 – ~Jan 2021 · 31 days · monthly snapshot~Jan 2021 – ~Apr 2021 · 3 months · monthly snapshot~Apr 2021 – present · 63 months · monthly snapshot

Change History

21 versions recorded

  1. Apr 2021 — Present [monthly]

    Completed PHASE3

    Status: Recruiting → Completed

  2. Jan 2021 — Apr 2021 [monthly]

    Recruiting PHASE3

  3. Dec 2020 — Jan 2021 [monthly]

    Recruiting PHASE3

  4. Oct 2020 — Dec 2020 [monthly]

    Recruiting PHASE3

  5. Sep 2020 — Oct 2020 [monthly]

    Recruiting PHASE3

▶ Show 16 earlier versions

  1. Aug 2020 — Sep 2020 [monthly]

    Recruiting PHASE3

  2. Jul 2020 — Aug 2020 [monthly]

    Recruiting PHASE3

  3. Jun 2020 — Jul 2020 [monthly]

    Recruiting PHASE3

  4. Jan 2020 — Jun 2020 [monthly]

    Recruiting PHASE3

  5. Dec 2019 — Jan 2020 [monthly]

    Recruiting PHASE3

  6. Aug 2019 — Dec 2019 [monthly]

    Recruiting PHASE3

  7. Jun 2019 — Aug 2019 [monthly]

    Recruiting PHASE3

  8. May 2019 — Jun 2019 [monthly]

    Recruiting PHASE3

  9. Nov 2018 — May 2019 [monthly]

    Recruiting PHASE3

  10. Oct 2018 — Nov 2018 [monthly]

    Recruiting PHASE3

  11. Sep 2018 — Oct 2018 [monthly]

    Recruiting PHASE3

  12. Jul 2018 — Sep 2018 [monthly]

    Recruiting PHASE3

  13. Jun 2018 — Jul 2018 [monthly]

    Recruiting PHASE3

  14. May 2018 — Jun 2018 [monthly]

    Recruiting PHASE3

  15. Mar 2018 — May 2018 [monthly]

    Recruiting PHASE3

  16. Jan 2018 — Mar 2018 [monthly]

    Recruiting PHASE3

    First recorded

Dec 2017

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Atara Biotherapeutics
Data source: Atara Biotherapeutics

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Adelaide, Australia , Atlanta, United States , Aurora, United States , Baltimore, United States , Boston, United States , Bronx, United States , Chapel Hill, United States , Charleston, United States , Charlotte, United States , Chicago, United States and 14 more locations